Indivior Study Finds Monthly Injectable Buprenorphine Lowers Relapse and Healthcare Use in OUD Patients
Indivior plc has presented new evidence on the impact of monthly injectable buprenorphine, SUBLOCADE®, for opioid use disorder (OUD) at the AMCP Nexus 2025 conference. The study shows that patients with high adherence to SUBLOCADE had lower relapse rates, reduced healthcare use, and better chronic disease management compared to those with low adherence. However, the study has limitations, including potential bias and the influence of the COVID-19 pandemic.
Indivior plc has announced new real-world evidence on the clinical and economic impact of monthly injectable buprenorphine, SUBLOCADE®, in the treatment of opioid use disorder (OUD). The results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference. Findings indicate that Medicaid and commercially insured patients with high adherence to SUBLOCADE experienced lower relapse rates, reduced healthcare resource utilization, lower rates of infectious disease complications, and improved chronic disease management compared to those with low adherence. The studies were based on retrospective claims and electronic health record data. Study limitations include potential bias due to the retrospective design, lack of adjustment for baseline differences, and possible impact from the COVID-19 pandemic. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior plc published the original content used to generate this news brief via PR Newswire (Ref. ID: PH12843) on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
